Pfizer: Prostatic Neoplasms trials
The registry lists 42 Prostatic Neoplasms studies with Pfizer as lead sponsor. 4 are open to participants now and 29 have results posted.
Phase 1 11Phase 2 14Phase 3 11Phase 4 1No phase 9(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.RecruitingNCT07028853Phase 3
- A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.RecruitingNCT06629779Phase 3
- Pre-approval Single-patient Expanded Access for Talazoparib (PF-06944076)AvailableNCT05650476
- Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid TumorsRecruitingNCT04557449Phase 2
- Description of Relugolix Use in Patients With Prostate Cancer Within the VHACompletedNCT06462014Results posted
- A Study to Learn About Novel Hormonal Therapies (NHTs) for Metastatic Castration-sensitive Prostate Cancer (mCSPC) in People Who Were in the Armed ForcesCompletedNCT06151418Results posted
- A Study to Learn About Novel Hormonal Therapies in People With Metastatic Castration-Sensitive Prostate Cancer (mCSPC)CompletedNCT06072196Results posted
- Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in FinlandCompletedNCT05701007Results posted
- Study to Compare the Effects of Repeated Doses of an Investigational New Drug and a Placebo on Appetite in Advanced Cancer and AnorexiaCompletedNCT04803305Phase 1Results posted
- A Bioequivalence Study Between the Proposed and Current Talazoparib Capsule Formulation and Food Effect Study for the Proposed Talazoparib Capsule Formulation in Participants With Advanced Solid TumorsCompletedNCT04672460Phase 1Results posted
- A Study of Ladiratuzumab Vedotin in Advanced Solid TumorsTerminatedNCT04032704Phase 2Results posted
- PF-06952229 Treatment in Adult Patients With Advanced Solid TumorsTerminatedNCT03685591Phase 1Results posted
- Tisotumab Vedotin Continued Treatment in Patients With Solid Tumors.CompletedNCT03245736Phase 2Results posted
- A Study of Talazoparib in Men With DNA Repair Defects and Metastatic Castration-Resistant Prostate CancerCompletedNCT03148795Phase 2Results posted
- A Phase 1 Study To Evaluate Escalating Doses Of A Vaccine-Based Immunotherapy Regimen For Prostate Cancer (PrCa VBIR)TerminatedNCT02616185Phase 1Results posted
- Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid TumorsCompletedNCT02552121Phase 1/2Results posted
- A Positron Emission Tomography/Computed Tomography (PET/CT) Bone Imaging Study in Patients Receiving Enzalutamide for Castration-Resistant Prostate Cancer (CRPC)CompletedNCT02384382Phase 2Results posted
- Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)Active, not recruitingNCT02319837Phase 3Results posted
- Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate CancerCompletedNCT02003924Phase 3Results posted
- Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid TumorsCompletedNCT02001623Phase 1/2Results posted
- Safety Study of Continued Enzalutamide Treatment In Prostate Cancer PatientsCompletedNCT01995513Phase 4Results posted
- Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate CancerCompletedNCT01664923Phase 2Results posted
- Safety and Tolerability Study of MDV3100 in Combination With Docetaxel in Men With Advanced Prostate CancerCompletedNCT01565928Phase 1Results posted
- Study of Enzalutamide (Formerly MDV3100) as a Neoadjuvant Therapy for Patients Undergoing Prostatectomy for Localized Prostate CancerCompletedNCT01547299Phase 2Results posted
- Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid TumorsCompletedNCT01286987Phase 1Results posted
- A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate CancerCompletedNCT01212991Phase 3Results posted
- Determine Effect of Enzalutamide (MDV3100) on the Androgen Signaling Pathway in Correlation With the Anti-tumor Effects of EnzalutamideCompletedNCT01091103Phase 2Results posted
- Figitumumab Combined With Pegvisomant For Advanced Solid TumorsTerminatedNCT00976508Phase 1Results posted
- Safety and Efficacy Study of MDV3100 in Patients With Castration-Resistant Prostate Cancer Who Have Been Previously Treated With Docetaxel-based ChemotherapyCompletedNCT00974311Phase 3Results posted
- Sunitinib Plus Prednisone In Patients With Metastatic Castration-Resistant Prostate Cancer After Failure Of Docetaxel ChemotherapyTerminatedNCT00676650Phase 3Results posted
- A Phase 1 Study of MDV3100 in Patients With Castration-Resistant (Hormone-Refractory) Prostate CancerCompletedNCT00510718Phase 1Results posted
- Study of CP-751,871 in Combination With Docetaxel and Prednisone in Patients With Hormone Insensitive Prostate Cancer (HRPC)CompletedNCT00313781Phase 2Results posted
- Study Of SU011248 In Combination With Docetaxel (Taxotere) And Prednisone In Patients With Prostate CancerCompletedNCT00137436Phase 1/2Results posted
- A Study to Learn About the Outcomes Between Study Medicines, Enzalutamide and Darolutamide Among Men With Metastatic Castration Sensitive Prostate Cancer (mCSPC)Active, not recruitingNCT07779590
- A Study to Learn About Two Medicines (Apalutamide and Enzalutamide) in People With Metastatic Castration-sensitive Prostate Cancer (mCSPC)CompletedNCT07086651
- A Study to Learn About the Safety of TALZENNA in People With Prostate Cancer.Active, not recruitingNCT06733337
- A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1).Active, not recruitingNCT06551324Phase 3
- Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPCActive, not recruitingNCT04821622Phase 3
- An Open Label Exploratory Study in Newly Diagnosed Prostate Cancer PatientsCompletedNCT00235794Not applicable
- Study of SGN-15, Antibody-Drug Conjugate, to Treat Hormone Refractory Prostate CancerCompletedNCT00031187Phase 2
- Mitoxantrone and Prednisone With or Without Leflunomide in Treating Patients With Stage IV Prostate CancerCompletedNCT00004071Phase 2/3
- Chemotherapy in Treating Patients Who Have Metastatic Prostate CancerCompletedNCT00003343Phase 3